Kevin King

Pfizer, Inc.

Kevin King is Senior Director, Portfolio & Project Management in Biotherapeutics Pharmaceutical Sciences at Pfizer. He is a biochemist and a graduate of the University of Wales, UK and has 25 years of experience in the development of biotherapeutics. He has worked previously at Hoffmann-La Roche (Switzerland), Procter & Gamble (UK) and Lonza Biologics, (UK).

As Senior Director of Portfolio and Project Management, Kevin is responsible for the interface between Research and Development covering the range of biotherapeutic modalities being developed globally at Pfizer.

Prior to that he was Senior Director, Analytical R&D where he was responsible for release and stability testing and monitoring of all clinical supplies (cell and gene therapies, monoclonal antibodies, fusion proteins, peptides, ADCs, oligonucleotides and vaccines) in the portfolio for biotherapeutic development in Pfizer Worldwide R&D. Kevin’s team also led the microbiological testing of biotherapeutic drug substance, drug product and cell bank facilities in Boston and St. Louis. He also partnered with Pfizer Global Supplies to transfer and validate analytical methods for testing of late stage supplies and prepare commercial QC groups to execute analytical testing. He also was accountable for maintaining a compliant organization and interacting with external regulatory inspectors and internal auditors. This role included execution of strategic outsourcing plans whilst creating robust and compliant external options for analytical testing and characterization.

In addition to this he has also been Senior Director, Formulation & Process Development where he led a group of pharmaceutical scientists involved in investigating biotherapeutic formulation stabilization technologies, formulation development, delivery technologies and applying the learnings in the formulation design of Pfizer’s biotherapeutic portfolio.